As of May 20, 2020, Zyla Life Sciences was acquired by Assertio Holdings, Inc. Zyla Life Sciences, a commercial-stage life sciences company, focuses on the development and marketing of various treatments for patients and healthcare providers. The company has a portfolio of various treatments for various types of pain and inflammation. Its commercial products include SPRIX nasal spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; ZORVOLEX, a novel formulation of diclofenac; VIVLODEX, a SoluMatrix formulation of meloxicam approved for osteoarthritis pain; INDOCIN suppositories; INDOCIN oral suspension products; and OXAYDO, an immediate-release oxycodone product for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate. The company was formerly known as Egalet Corporation. Zyla Life Sciences was founded in 2010 and is headquartered in Wayne, Pennsylvania.